Needed relapse-prevention research on novel framework (aspire model) for substance use disorders treatment

Frontiers in Psychiatry

Volumn 6, Issue MAR, 2015, Pages

  Ghitza, Udi E ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Addiction; Addiction treatment; Addictive disorders; Drug abuse; Drug abuse treatment; Personalized medicine; Precision medicine; Substance abuse

Indexed keywords

ILLICIT DRUG;

ARTICLE; ASPIRE MODEL; CONCEPTUAL FRAMEWORK; DATA ANALYSIS; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MEDICAL SERVICE; MEDICAL SOCIETY; NONBIOLOGICAL MODEL; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; RELAPSE PREVENTION RESEARCH; SUBSTANCE ABUSE; UNITED STATES;

EID: 84926661911     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2015.00037     Document Type: Article

References (30)

1. Substance Abuse and Mental Health Services Administration. Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration (2014).
2. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the global burden of disease study 2010. Lancet (2013) 382:1564-74. doi: 10.1016/S0140-6736(13)61530-5
3. Ghitza UE, Tai B. Challenges and opportunities for integrating preventive substance-use-care services in primary care through the Affordable Care Act. J Health Care Poor Underserved (2014) 25:36-45. doi:10.1353/hpu.2014.0067
4. Bradley KA, Kivlahan DR. Bringing patient-centered care to patients with alcohol use disorders. JAMA (2014) 311:1861-2. doi:10.1001/jama.2014.3629
5. Légaré F, Witteman HO. Shared decision making: examining key elements and barriers to adoption into routine clinical practice. Health Aff (Millwood) (2013) 32:276-84. doi:10.1377/hlthaff.2012.1078
6. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med (2012) 27:1361-7. doi:10.1007/s11606-012-2077-6
7. Ghitza UE. ASPIRE model for treating cannabis and other substance use disorders: a novel personalized-medicine framework. Front Psychiatry (2014) 5:180. doi:10.3389/fpsyt.2014.00180
8. Wise RA, Koob GF. The development and maintenance of drug addiction. Neuropsychopharmacology (2014) 39:254-62. doi:10.1038/npp.2013.261
9. Jobes ML, Ghitza UE, Epstein DH, Phillips KA, Heishman SJ, Preston KL. Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology (Berl) (2011) 218:83-8. doi:10.1007/s00213-011-2230-7
10. McKee SA, Potenza MN, Kober H, Sofuoglu M, Arnsten AF, Picciotto MR, et al. A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation. J Psychopharmacol (2014). doi:10.1177/0269881114562091
11. Fox H, Sinha R. The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals. Adv Pharmacol (2014) 69:217-65. doi:10.1016/B978-0-12-420118-7.00006-8
12. Sinha R, Kimmerling A, Doebrick C, Kosten TR. Effects of lofexidine on stress-induced and cue-induced opioid craving and opioid abstinence rates: preliminary findings. Psychopharmacology (Berl) (2007) 190:569-74. doi:10.1007/s00213-006-0640-8
13. Fox HC, Tuit KL, Sinha R. Stress system changes associated with marijuana dependence may increase craving for alcohol and nicotine. Hum Psychopharmacol (2013) 1:40-53. doi:10.1002/hup.2280
14. Fox H, Sofuoglu M, Sinha R. Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals. J Psychopharmacol (2015). doi:10.1177/0269881114562464
15. U.S. Food and Drug Administration (FDA). Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. Silver Spring, MD: FDA (2012).
16. Babson KA, Boden MT, Bonn-Miller MO. The impact of perceived sleep quality and sleep efficiency/duration on cannabis use during a self-guided quit attempt. Addict Behav (2013) 38:2707-13. doi:10.1016/j.addbeh.2013.06.012
17. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend (2011) 119:123-9. doi:10.1016/j.drugalcdep.2011.06.003
18. Brooks AT, Wallen GR. Sleep disturbances in individuals with alcohol-related disorders: a review of cognitive-behavioral therapy for insomnia (CBT-I) and associated non-pharmacological therapies. Subst Abuse (2014) 8:55-62. doi:10.4137/SART.S18446
19. Matuskey D, Pittman B, Forselius E, Malison RT, Morgan PT. A multistudy analysis of the effect of early cocaine abstinence on sleep. Drug Alcohol Depend (2011) 115:62-6. doi:10.1016/j.drugalcdep.2010.10.015
20. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res (2007) 9:315-27. doi:10.1080/14622200701188919
21. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized controlled trial. JAMA Intern Med (2014) 174:70-7. doi:10.1001/jamainternmed.2014.1591
22. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology (2012) 37:1689-98. doi:10.1038/npp.2012.14
23. McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs (2014) 28:95-106. doi:10.1007/s40263-014-0142-x
24. Grandjean EM, Berthet P, Ruffman R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther (2000) 22:209-21. doi:10.1016/S0149-2918(00)88479-9
25. Reissner KJ, Gipson CD, Tran PK, Knackstedt LA, Scofield MD, Kalivas PW. Glutamate transporter GLT-1 mediates N-acetylcysteine inhibition of cocaine reinstatement. Addict Biol (2014) 20(2):316-23. doi:10.1111/adb.12127
26. Reissner KJ, Brown RM, Spencer S, Tran PK, Thomas CA, Kalivas PW. Chronic administration of the methylxanthine propentofylline impairs reinstatement to cocaine by a GLT-1-dependent mechanism. Neuropsychopharmacology (2014) 39:499-506. doi:10.1038/npp.2013.223
27. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry (2012) 169:805-12. doi:10.1176/appi.ajp.2012.12010055
28. McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, et al. Achieving cannabis cessation - evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the national institute on drug abuse clinical trials network. Contemp Clin Trials (2014) 39:211-23. doi:10.1016/j.cct.2014.08.011
29. Sunitha K, Hemshekhar M, Thushara RM, Santhosh MS, Yariswamy M, Kemparaju K, et al. N-acetylcysteine amide: a derivative to fulfill the promises of N-acetylcysteine. Free Radic Res (2013) 47:357-67. doi:10.3109/10715762.2013.781595
30. Tai B, Sparenborg S, Ghitza UE, Liu D. Expanding the national drug abuse treatment clinical trials network to address the management of substance use disorders in general medical settings. Subst Abuse Rehabil (2014) 5:75-80. doi:10.2147/SAR.S66538